Drug Safety

, Volume 22, Issue 2, pp 111–122 | Cite as

Corticosteroid-Induced Adverse Psychiatric Effects

Incidence, Diagnosis and Management
Review Article

Abstract

Reports of corticosteroid-induced adverse psychiatric effects began to appear in the literature soon after the introduction of these medications in the 1950s. Unfortunately, early studies relied on informal classification and measurement procedures and tended to utilise nonspecific descriptive terminology (such as ‘steroid psychosis’). A growing number of contemporary investigations have begun to address these problems. However, the literature remains surprisingly undeveloped from a pharmacoepidemiological perspective, consisting largely of case reports and case series.

The objective of this review is to summarise published data concerning corticosteroid-induced adverse psychiatric effects. A clinical perspective will be adopted since opportunities to minimise the impact of corticosteroid-induced adverse effects tend to present themselves most readily within the sphere of clinical management.

Some of the psychiatric adverse effects of corticosteroids are mild, and not necessarily clinically significant. However, several serious psychiatric syndromes can be caused by corticosteroids: substance-induced mood disorders (with depressive, manic and mixed features), substance-induced psychotic disorders and delirium. While certain clinical groups may be at greater risk of corticosteroid-induced adverse psychiatric effects, corticosteroid-induced psychiatric toxicity is remarkably unpredictable.

The literature regarding prevention and treatment of corticosteroid-induced adverse psychiatric effects is poorly developed. As a result, the emphasis of this review is on clinical and epidemiological evidence linking specific adverse effects to corticosteroid medications. However, clinical reports do provide some practical guidance for prevention and treatment, and these are summarised as well. A variety of pharmacological strategies for treatment and prevention have been proposed. Education and support also appear to be important, and perhaps neglected, aspects of management.

References

  1. 1.
    Clark LD, Quarton GC, Cobb S, et al. Further observations on mental disturbances associated with cortisone and ACTH therapy. N Engl J Med 1953; 249: 178–83PubMedCrossRefGoogle Scholar
  2. 2.
    Clark LD, Bauer W, Cobb S. Preliminary observations on mental disturbances occurring in patients under therapy with cortisone and ACTH. N Engl J Med 1952; 246: 205–16PubMedCrossRefGoogle Scholar
  3. 3.
    Ritchie EA. Toxic psychosis under cortisone and corticotrophin. J Ment Sci 1956; 102: 830–7PubMedGoogle Scholar
  4. 4.
    Goolker P, Schein J. Psychic effects of ACTH and cortisone. Psychosom Med 1953; 15: 589–613PubMedGoogle Scholar
  5. 5.
    Mitchell DM, Collins JV. Do corticosteroids really alter mood? Postgrad Med J 1984; 60: 467–70PubMedCrossRefGoogle Scholar
  6. 6.
    Conn HO, Poynard T. Corticosteroids and peptic ulcer: metaanalysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619–32PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen SI. Cushing’s syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980; 136: 120–4PubMedCrossRefGoogle Scholar
  8. 8.
    Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing’s syndrome: relationship to hormone levels. Psychosom Med 1981; 43(1): 3–18PubMedGoogle Scholar
  9. 9.
    Kelly WF, Checkley SA, Bender DA, et al. Cushing’s syndrome and depression - a prospective study of 26 patients. Br J Psychiatry 1983; 142: 16–9PubMedCrossRefGoogle Scholar
  10. 10.
    Kelly WF, Checkley SA, Bender DA. Cushing’s syndrome, tryptophan and depression. Br J Psychiatry 1980; 136: 125–32PubMedCrossRefGoogle Scholar
  11. 11.
    Pies RP. Differential diagnosis and treatment of steroid-induced affective syndromes. Gen Hosp Psychiatry 1995; 17: 353–61PubMedCrossRefGoogle Scholar
  12. 12.
    Rome HP, Braceland FJ. The psychological response to ACTH, cortisone, hydrocortisone, and related steroid substances. Am J Psychiatry 1952; 108: 641–51PubMedGoogle Scholar
  13. 13.
    Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30(2): 135–9PubMedCrossRefGoogle Scholar
  14. 14.
    Silva RG, Tolstunov L. Steroid-induced psychosis: report of case. J Oral Maxillofac Surg 1995; 53: 183–6PubMedCrossRefGoogle Scholar
  15. 15.
    Stoudemire A, Anfinson T, Edwards J. Corticosteroid-induced delirium and dependency. Gen Hosp Psychiatry 1996; 18: 196–202PubMedCrossRefGoogle Scholar
  16. 16.
    Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7: 479–91PubMedCrossRefGoogle Scholar
  17. 17.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association, 1994Google Scholar
  18. 18.
    Mullen RS, Romans-Clarkson SE. Behavioural sensitisation and steroid-induced psychosis. Br J Psychiatry 1993; 162: 549–51PubMedCrossRefGoogle Scholar
  19. 19.
    Greeves JA. Rapid-onset steroid psychosis with very low dosage of prednisolone [letter]. Lancet 1984; I: 1119–20CrossRefGoogle Scholar
  20. 20.
    Gift AG, Wood RM, Cahill CA. Depression, somatization and steroid use in chronic obstructive pulmonary disease. Int J Nurs Stud 1989; 26: 281–6PubMedCrossRefGoogle Scholar
  21. 21.
    Patten SB, Williams JVA, Love EJ. Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study. Can J Psychiatry 1995; 40: 264–9PubMedGoogle Scholar
  22. 22.
    Palinkas LA, Wingard DL, Barrett-Connor E. Chronic illness and depressive symptoms in the elderly: a population-based study. J Clin Epidemiol 1990; 43(11): 1131–41PubMedCrossRefGoogle Scholar
  23. 23.
    Patten SB, Williams JVA, Love EJ. Self-reported depressive symptoms following treatment with corticosteroids and sedative-hypnotics. Int J Psychiatry Med 1996; 26(1): 15–24PubMedCrossRefGoogle Scholar
  24. 24.
    Patten SB, Williams JVA, Love EJ. A case-control study of corticosteroid exposure as a risk factor for clinically-diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1995; 40: 396–400PubMedGoogle Scholar
  25. 25.
    Arana GW, Santos AB, Laraia MT, et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind study. Am J Psychiatry 1995; 152: 265–7PubMedGoogle Scholar
  26. 26.
    Soffer LJ, Levitt MF, Baehr G. Use of cortisone and adrenocorticotropic hormone in acute disseminated lupus erythematosus. Arch Intern Med 1950; 86: 558–73CrossRefGoogle Scholar
  27. 27.
    Terao T, Mizuki T, Ohji T, et al. Antidepressant effect of lithium in patients with systemic lupus erythematosus and cerebral infarction, treated with corticosteroids. Br J Psychiatry 1994; 164: 109–11PubMedCrossRefGoogle Scholar
  28. 28.
    Baker M, Hadler NM, Whitaker JN, et al. Psychopathology in systemic lupus erythematosus: II: relation to clinical observations, corticosteroid administration, and cerebrospinal fluid C4. Semin Arthritis Rheum 1973; 3: 111–26PubMedCrossRefGoogle Scholar
  29. 29.
    Jones BD, Chouinard G. Clonazepam in the treatment of recurrent symptoms of depression and anxiety in a patient with systemic lupus erythematosus. Am J Psychiatry 1985; 142: 354–5PubMedGoogle Scholar
  30. 30.
    Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment: a prospective study. Psychoneuroendocrinology 1996; 21: 25–31PubMedCrossRefGoogle Scholar
  31. 31.
    Rundell JR, Wise MG. Causes of organic mood disorder. J Neuropsychiatry Clin Neurosci 1989; 1: 398–400PubMedGoogle Scholar
  32. 32.
    Sharfstein SS, Sack DS, Fauci AS. Relationship between alternate-day corticosteroid therapy and behavioral abnormalities. JAMA 1982; 248: 2987–9PubMedCrossRefGoogle Scholar
  33. 33.
    Joffe RT, Denicoff KD, Rubinow DR, et al. Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. Gen Hosp Psychiatry 1988; 10: 56–60PubMedCrossRefGoogle Scholar
  34. 34.
    Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 1988; 38: 1631–4PubMedCrossRefGoogle Scholar
  35. 35.
    Fishman SM, Catarau EM, Sachs GM, et al. Corticosteroid-induced mania after single regional application at the celiac plexus. Anesthiology 1996; 85: 1194–6CrossRefGoogle Scholar
  36. 36.
    Phelan MC. Beclomethason mania. Br J Psychiatry 1989; 155: 871–2PubMedCrossRefGoogle Scholar
  37. 37.
    Meyboom RH. Budesonide and psychic side effects [letter]. Ann Intern Med 1988; 109: 683PubMedGoogle Scholar
  38. 38.
    Lewis LD, Cochrane GM. Psychosis in a child inhaling budesonide [letter]. Lancet 1983; II: 634CrossRefGoogle Scholar
  39. 39.
    Pies R. Persistent bipolar illness after steroid administration. Arch Intern Med 1981; 141: 1087PubMedCrossRefGoogle Scholar
  40. 40.
    Bell G. Steroid-induced psychiatric disorders. Nord Psykiatr Tidsskr 1991; 45: 437–41CrossRefGoogle Scholar
  41. 41.
    Hall RCW, Popkin MK, Stickney SK, et al. Presentation of the steroid psychoses. J Nerv Ment Dis 1979; 167`(4): 229–36Google Scholar
  42. 42.
    Baloch N. ‘Steroid psychosis’: a case report. Br J Psychiatry 1974; 124: 545–6PubMedCrossRefGoogle Scholar
  43. 43.
    Yunus MB, Morgan RJ, Barclay AM, et al. Organic brain syndrome in rheumatoid arthritis after corticosteroid withdrawal [letter]. J Rheumatol 1985; 12: 636–7PubMedGoogle Scholar
  44. 44.
    Perenyi A, Frecska E, Badgy G, et al. Panic attacks as a consequence of chronic corticosteroid therapy? Eur J Psychiatry 1988; 2: 69–74Google Scholar
  45. 45.
    Wyszynski AA, Wyszynski B. Treatment of depression with fluoxetine in corticosteroid-dependent central nervous system Sjogren’s syndrome. Psychosomatics 1993; 34(2): 173–7PubMedCrossRefGoogle Scholar
  46. 46.
    Cade R, Spooner G, Schlein E, et al. Comparison of azothioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 1973; 10: 37–56PubMedCrossRefGoogle Scholar
  47. 47.
    Wysenbeek AJ, Leibovici L, Zoldan J. Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus. J Rheumatol 1990; 17: 1695–6PubMedGoogle Scholar
  48. 48.
    Marx FW, Barker WF. Surgical results in patients with ulcerative colitis treated with and without corticosteroids. Am J Surg 1967; 113: 157–63PubMedCrossRefGoogle Scholar
  49. 49.
    Turktas I, Gucuyener K, Ozden A. Medication-induced psychotic reaction [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36: 1017–8PubMedCrossRefGoogle Scholar
  50. 50.
    Walkowitz OM. Prospective controlled studies of the behavioural and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994; 19: 233–55CrossRefGoogle Scholar
  51. 51.
    Lidz T, Carter JD, Lewis BI, et al. Effects of ACTH and cortisone on mood and mentation. Psychosom Med 1952; 24: 363–77Google Scholar
  52. 52.
    Cameron OG, Addy RO, Malitz D. Effects of ACTH and prednisone on mood: incidence and time of onset. Int J Psychiatry Med 1985; 15: 213–23PubMedCrossRefGoogle Scholar
  53. 53.
    Swinburn CR, Wakefield JM, Newman SP, et al. Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease. Br J Clin Pharmacol 1988; 26: 709–13PubMedCrossRefGoogle Scholar
  54. 54.
    Morgan HG, Boulnois J, Burns-Cox C. Addiction to prednisone. BMJ 1973; 2: 93–4PubMedCrossRefGoogle Scholar
  55. 55.
    Kimball CP. Psychological dependency on steroids? Ann Intern Med 1971; 75: 111–3PubMedGoogle Scholar
  56. 56.
    Brown ES. Chemical dependence involving glucocorticoids. Ann Clin Pschiatry 1997; 9: 185–7Google Scholar
  57. 57.
    Grigg JR. Prednisone mood disorder with associated catatonia. J Geriatr Psychiatry Neurol 1989; 2: 41–4PubMedCrossRefGoogle Scholar
  58. 58.
    Sullivan BJ, Dickerman JD. Steroid-associated catatonia: report of a case. Pediatrics 1979; 63: 677–9PubMedGoogle Scholar
  59. 59.
    Varney NR, Alexander B, MacIndoe JH. Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry 1994; 141: 369–72Google Scholar
  60. 60.
    Suess WM, Stump N, Chai H, et al. Mnemonic effects of asthma medication in children. J Asthma 1986; 23: 291–6PubMedCrossRefGoogle Scholar
  61. 61.
    Bender BG, Lerner JA, Kollasch E. Mood and memory changes in asthmatic children receiving corticosteroids. J Am Acad Child Adolesc Psychiatry 1988; 27: 720–5PubMedCrossRefGoogle Scholar
  62. 62.
    Arnold LE. Increased arousal from steroids? J Am Acad Child Adolesc Psychiatry 1989; 28: 618–9Google Scholar
  63. 63.
    Bender BG. Drs Bender and Lerner reply. J Am Acad Child Adolesc Psychiatry 1989; 28: 619CrossRefGoogle Scholar
  64. 64.
    Hall RCW, Popkin MK, Kirkpatrick B. Tricyclic exacerbation of steroid psychosis. J Nerv Ment Dis 1978; 166: 738–42PubMedCrossRefGoogle Scholar
  65. 65.
    Wolkowitz OM, Reus VI, Weingartner H, et al. Cognitive effects of corticosteroids. Am J Psychiatry 1990; 147: 1297–303PubMedGoogle Scholar
  66. 66.
    Newcomer JW, Craft S, Hershey T, et al. Glucocorticoid-induced impairments in declarative memory performance in adult humans. J Neurosci 1994; 14: 2047–53PubMedGoogle Scholar
  67. 67.
    Connett G, Lenney W. Inhaled budesonide and behavioural disturbances [letter]. Lancet 1991; 338: 636–5CrossRefGoogle Scholar
  68. 68.
    Harris JC, Carel CA, Rosenberg LA, et al. Intermittent high dose corticosteroid treatment in childhood cancer: behavioral and emotional consequences. J Am Acad Child Adolesc Psychiatry 1986; 1: 120–4Google Scholar
  69. 69.
    Hassanyeh F, Murray RB, Rodgers H. Adrenocortical suppression presenting with agitated depression, morbid jealousy, and a dementia-like state. Br J Psychiatry 1991; 159: 870–2PubMedCrossRefGoogle Scholar
  70. 70.
    Kreus KE, Viljanen AA, Kujula E, et al. Treatment of steroid-dependent asthma patients with beclomethasone dipropionate aerosol. Scand J Respir Med 1975; 56: 47–57Google Scholar
  71. 71.
    Lewis A, Fleminger JJ. The psychiatric risk from corticotrophin and cortisone. Lancet 1954; I: 383–6CrossRefGoogle Scholar
  72. 72.
    Vincent FM. The neuropsychiatric complications of corticosteroid therapy. Compr Ther 1995; 21: 524–8PubMedGoogle Scholar
  73. 73.
    Goggans FC, Weisberg LJ, Koran LM. Lithium prophylaxis of prednisone psychosis: a case report. J Clin Psychiatry 1983; 44: 111–2PubMedGoogle Scholar
  74. 74.
    Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990; 19: 126–46PubMedCrossRefGoogle Scholar
  75. 75.
    Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 1983; 5: 319–32PubMedCrossRefGoogle Scholar
  76. 76.
    Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276(4): 293–9PubMedCrossRefGoogle Scholar
  77. 77.
    Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13: 694–8Google Scholar
  78. 78.
    Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128: 1467–73PubMedCrossRefGoogle Scholar
  79. 79.
    Glynne-Jones R, Vernon CC, Bell G. Is steroid psychosis preventable by divided doses [letter]. Lancet 1986; II: 1404CrossRefGoogle Scholar
  80. 80.
    Cordess C, Folstein M, Drachman D. Psychiatric effects of alternate day steroid therapy. Br J Psychiatry 1981; 138: 504–6PubMedCrossRefGoogle Scholar
  81. 81.
    Finkenbine R, Gill HS. Case of mania due to prednisone-clarithromycin interaction [letter]. Can J Psychiatry 1997; 42: 778PubMedGoogle Scholar
  82. 82.
    Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotrophin-induced psychosis. JAMA 1979; 241(10): 1011–2PubMedCrossRefGoogle Scholar
  83. 83.
    Siegal FP. Lithium for steroid-induced psychosis [letter]. N Engl J Med 1978; 299: 155–6PubMedCrossRefGoogle Scholar
  84. 84.
    Sabet-Sharghi F, Hutzler JC. Prophylaxis of steroid-induced psychiatric syndromes [letter]. Psychosomatics 1990; 31: 113–4PubMedCrossRefGoogle Scholar
  85. 85.
    Saklad SR. Management of corticosteroid-induced psychosis with lithium. Clin Pharm 1987; 6: 186PubMedGoogle Scholar
  86. 86.
    Lynn DJ. Lithium in steroid-induced depression [letter]. Br J Psychiatry 1994; 166: 264CrossRefGoogle Scholar
  87. 87.
    Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40: 301–8PubMedGoogle Scholar
  88. 88.
    Bloch M, Gur E, Shalev A. Chlorpromazine prophylaxis of steroid-induced psychosis. Gen Hosp Psychiatry 1994; 16: 42–4PubMedCrossRefGoogle Scholar
  89. 89.
    Abbas A, Stryra R. Valproate prophylaxis against steroid induced psychosis [letter]. Can J Psychiatry 1994; 39: 188–9PubMedGoogle Scholar
  90. 90.
    Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry 1988; 145: 1010–1PubMedGoogle Scholar
  91. 91.
    Brown ES, Khan DA, Suppes T. Treatment of corticosteroid-induced mood changes with olanzapine [letter]. Am J Psychiatry 1999; 156: 968PubMedGoogle Scholar
  92. 92.
    Blazer DG, Petrie WM, Wilson WP. Affective psychosis following renal transplant. Dis Nerv Syst 1976; 37: 663–7PubMedGoogle Scholar
  93. 93.
    Terao T, Yoshimura R, Shiratuchi T, et al. Effects of lithium on steroid-induced depression. Biol Psychiatry 1997; 41: 1225–6PubMedCrossRefGoogle Scholar
  94. 94.
    Ismail K, Wessely S. Psychiatric complications of corticosteroid therapy. Br J Hosp Med 1995; 53: 495–9PubMedGoogle Scholar
  95. 95.
    Bräunig P, Bleistein J, Rao ML. Suicidality and corticosteroid-induced psychosis [letter]. Biol Psychiatry 1989; 26: 209–10PubMedCrossRefGoogle Scholar
  96. 96.
    Reckart MD, Eisendrath SJ. Exogenous corticosteroid effects on mood and cognition: case presentation. Int J Psychosom 1990; 37: 57–61PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of Community Health Sciences and Department of Psychiatry, Faculty of MedicineThe University of CalgaryCalgary, AlbertaCanada
  2. 2.Bureau of Drug Surveillance, Therapeutic Products Program, Health CanadaOttawa, OntarioCanada

Personalised recommendations